EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Antiosteoporosis therapy after discontinuation of menopausal hormone therapy: a systematic review

Panagiotis Anagnostis, Efstathios Divaris, Julia Κ Bosdou, Symeon Tournis, Konstantinos Stathopoulos, Dimitrios G Goulis

Hormones · 2024-06 · 23 (2) · 339-344

DOI: 10.1007/s42000-024-00526-1 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Hormones, online erschienen am 18.01.2024. Verfasst von Panagiotis Anagnostis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, …. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Osteoporosis, Postmenopausal, Bone Density. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Aristotle University of Thessaloniki.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Menopausal hormone therapy (MHT) has consistently shown a bone protective effect by reducing the risk of vertebral, non-vertebral, and hip fractures in postmenopausal women regardless of baseline fracture risk. However, the optimal sequential treatment after MHT discontinuation has not been determined. This systematic review aimed to obtain the best evidence regarding the effect of antiresorptive or osteoanabolic treatment on bone mineral density (BMD) and/or fracture risk following MHT.

Methods

A comprehensive search was conducted in the PubMed, Scopus, and Cochrane databases up to October 31, 2023. Randomized-controlled trials (RCTs) and observational studies conducted in postmenopausal women were included.

Results

After the exclusion of duplicates, 717 studies were identified. Two were eligible for qualitative analysis, one RCT and one retrospective cohort study. The RCT showed that alendronate 10 mg/day for 12 months further increased lumbar spine (LS) BMD by 2.3% following MHT and maintained femoral neck (FN) BMD in postmenopausal women (n = 144). It also decreased bone anabolic and resorption markers by 47 and 36%, respectively. In the retrospective study (n = 34), raloxifene 60 mg/day increased both LS and FN BMD at 12 months by 3 and 2.9%, respectively. No fractures were reported.

Conclusions

Antiresorptive therapy with either a bisphosphonate (i.e., alendronate) or raloxifene could be considered a sequential antiosteoporosis therapy after MHT withdrawal since they have been shown in studies to further increase BMD. However, no safe conclusions can be drawn from the existing literature.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Density Conservation AgentsOsteoporosis, PostmenopausalBone DensityHumansFemaleEstrogen Replacement Therapy

Stichwörter der Autor:innen

AlendronateBisphosphonatesEstrogenMenopausal hormone therapyPostmenopausal womenRaloxifene

Substanzen

Bone Density Conservation Agents

Autor:innen und Institutionen

  • Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece. anagnwstis.pan@yahoo.gr.
  • Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Unit for Human Reproduction, 1st Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Laboratory for the Research of Musculoskeletal System "Th. Garofalidis," School of Medicine, National and Kapodistrian University of Athens, KAT General Hospital, Athens, Greece.
  • School of Medicine, Post Graduate Course on Bone Metabolic Diseases, National and Kapodistrian University of Athens, Mikras Asias 75, 11527, Athens, Greece.

Förderung

  • Aristotle University of Thessaloniki

Zitieren

APA

Anagnostis, P., Divaris, E., Bosdou, J. Κ., Tournis, S., Stathopoulos, K., & Goulis, D. G. (2024). Antiosteoporosis therapy after discontinuation of menopausal hormone therapy: a systematic review. Hormones, 23(2), 339-344. https://doi.org/10.1007/s42000-024-00526-1

Vancouver

Anagnostis P, Divaris E, Bosdou JΚ, Tournis S, Stathopoulos K, Goulis DG. Antiosteoporosis therapy after discontinuation of menopausal hormone therapy: a systematic review. Hormones. 2024;23(2):339-344. doi:10.1007/s42000-024-00526-1

BibTeX
@article{Anagnostis2024,
  author = {Anagnostis, Panagiotis and Divaris, Efstathios and Bosdou, Julia Κ and Tournis, Symeon and Stathopoulos, Konstantinos and Goulis, Dimitrios G},
  title = {Antiosteoporosis therapy after discontinuation of menopausal hormone therapy: a systematic review},
  journal = {Hormones},
  year = {2024},
  volume = {23},
  number = {2},
  pages = {339--344},
  doi = {10.1007/s42000-024-00526-1}
}
Kostenlos starten →